ATE251466T1 - Zusammensetzung auf basis gegensätzlich geladener polypeptide - Google Patents

Zusammensetzung auf basis gegensätzlich geladener polypeptide

Info

Publication number
ATE251466T1
ATE251466T1 AT00920012T AT00920012T ATE251466T1 AT E251466 T1 ATE251466 T1 AT E251466T1 AT 00920012 T AT00920012 T AT 00920012T AT 00920012 T AT00920012 T AT 00920012T AT E251466 T1 ATE251466 T1 AT E251466T1
Authority
AT
Austria
Prior art keywords
composition based
oppositely charged
charged polypeptides
polypeptides
beta
Prior art date
Application number
AT00920012T
Other languages
English (en)
Inventor
James Q Oeswein
John R Smikahl
Sharon X Wang
Douglas A Yeung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE251466T1 publication Critical patent/ATE251466T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/808—Optical sensing apparatus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Hydrogenated Pyridines (AREA)
AT00920012T 1999-04-08 2000-03-30 Zusammensetzung auf basis gegensätzlich geladener polypeptide ATE251466T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12839299P 1999-04-08 1999-04-08
PCT/US2000/008682 WO2000061177A1 (en) 1999-04-08 2000-03-30 Composition based on oppositely-charged polypeptides

Publications (1)

Publication Number Publication Date
ATE251466T1 true ATE251466T1 (de) 2003-10-15

Family

ID=22435148

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920012T ATE251466T1 (de) 1999-04-08 2000-03-30 Zusammensetzung auf basis gegensätzlich geladener polypeptide

Country Status (13)

Country Link
US (2) US6559122B1 (de)
EP (1) EP1165119B1 (de)
JP (2) JP4360758B2 (de)
AT (1) ATE251466T1 (de)
AU (1) AU763039B2 (de)
CA (1) CA2369451C (de)
DE (1) DE60005806T2 (de)
DK (1) DK1165119T3 (de)
ES (1) ES2208305T3 (de)
HK (1) HK1039065B (de)
IL (1) IL145597A0 (de)
PT (1) PT1165119E (de)
WO (1) WO2000061177A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
ATE251466T1 (de) * 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6689747B2 (en) * 2000-03-24 2004-02-10 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
AU2003219958B2 (en) * 2002-02-27 2006-01-05 Immunex Corporation Polypeptide formulation
EP1523326A4 (de) 2002-05-06 2009-09-09 Univ Jefferson Insulin-assoziierte peptide zur besserung der gehirnwirkung
JP2006514990A (ja) * 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
JP5014116B2 (ja) * 2004-03-11 2012-08-29 ジェネンテック， インコーポレイテッド ポリペプチドの精製
EP2708225B1 (de) 2004-04-23 2018-12-26 CyDex Pharmaceuticals, Inc. Sulfoalkylethercyclodextrin enthaltende DPI-Formulierung
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CN101484469B (zh) * 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP2968574A1 (de) * 2013-03-14 2016-01-20 Allergan, Inc. Zusammensetzung mit verzögerter freisetzung und verfahren zur stabilisierung von proteinen während des herstellungsverfahrens
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US5077276A (en) 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU607209B2 (en) 1987-04-23 1991-02-28 Monsanto Technology Llc Secretion of insulin-like growth factor-i in e. coli
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
WO1989003840A1 (en) 1987-10-23 1989-05-05 Schering Corporation Method of purifying protein
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU671964B2 (en) 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Peroral administration form for peptidic medicaments, in particular insulin
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
SE9300105D0 (sv) 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
JPH08500123A (ja) 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
SE9402119D0 (sv) 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5788959A (en) 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
PT986404E (pt) 1996-07-10 2002-09-30 West Pharm Serv Drug Res Ltd Sistema de entrega de terapia genica com alvo no endotelio
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
WO1999024063A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Compositions providing for increased igf-i solubility
ATE251466T1 (de) * 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide

Also Published As

Publication number Publication date
DE60005806T2 (de) 2004-08-05
AU4061300A (en) 2000-11-14
US20030195142A1 (en) 2003-10-16
JP2002541212A (ja) 2002-12-03
HK1039065B (zh) 2004-04-16
IL145597A0 (en) 2002-06-30
HK1039065A1 (en) 2002-04-12
JP2009029803A (ja) 2009-02-12
US7186686B2 (en) 2007-03-06
DE60005806D1 (de) 2003-11-13
EP1165119A1 (de) 2002-01-02
WO2000061177A9 (en) 2002-04-18
ES2208305T3 (es) 2004-06-16
JP4360758B2 (ja) 2009-11-11
US6559122B1 (en) 2003-05-06
WO2000061177A1 (en) 2000-10-19
DK1165119T3 (da) 2003-12-15
CA2369451C (en) 2009-09-22
AU763039B2 (en) 2003-07-10
PT1165119E (pt) 2004-02-27
CA2369451A1 (en) 2000-10-19
EP1165119B1 (de) 2003-10-08

Similar Documents

Publication Publication Date Title
ATE251466T1 (de) Zusammensetzung auf basis gegensätzlich geladener polypeptide
DE69329425T2 (de) Dolastatin analog
ATE380822T1 (de) Funf-helix protein
PT689459E (pt) Novo agente para o controlo da actividade celular
CO5540371A2 (es) Administracion pulmonar de insulina quimicamente modificada
FI973048A (fi) Menetelmät ja koostumukset hydrofiilisten molekyylien lipidisoimiseksi
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
DE69126568D1 (de) Neues physiologisch aktives Schweinepeptid (CNP-53)
BR0011040A (pt) Revestimento de pó de mate
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU5690400A (en) Novel compounds
DK0921793T3 (da) Faste, ikke-henflydende formuleringer af natriumvalproat
NZ232564A (en) Pseudomonas exotoxin a, pe40 domain derivatives conjugated to a protein targeting domain
ES2156611T3 (es) Metodo para acoplar polisacaridos a proteinas.
DE69737476D1 (de) Neuer galaninrezeptor
MX9800967A (es) Compuestos quimicos.
ES1054933Y (es) Colector de orina perfeccionado de uso femenino.
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
RS52910B (en) POLYMER CONJUGATES OF MUTATED NEUBLASTINE
BR9910763A (pt) Proteìna não-estrutural 4 (nsp4) de rotavìrus composição antigênica, processos para proteger um hospedeiro mamìfero contra doença causada por rotavìrus, e para melhorar sintomas diarréicos em um hospedeiro mamìfero, sequência de ácido nucleico isolada e purificada, plasmìdeo contendo uma sequência de ácido nucleico isolada e purificada, célula hospedeira, e, processo para produzir uma forma alternativa de nsp4 de rotavìrus
AU2001237784A1 (en) Method for fixing that part of a flashing, made of lead-replacement material, that is fitted in a joint between two structural components, and clamping body to be used for this
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
IT1262906B (it) Proteine funzionalizzate e loro uso per la preparazione di traccianti coniugati
AU8020298A (en) Leukotriene B4 derivatives, in particular 7-methylcyclohexyl-LTB4 antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165119

Country of ref document: EP